The new regulations, published after a years-long review process involving patient advocacy groups, medical experts, and regional consultations in 25 departments, mark the most significant update to Colombia’s Plan de Beneficios en Salud (PBS) since 2017. While the government frames the changes as necessary to ensure sustainable funding for essential services, critics warn the exclusions could disproportionately affect low-income patients who rely on public health coverage for chronic conditions and routine care.

Among the most controversial exclusions are minoxidil for alopecia (hair loss), diacerein for osteoarthritis, and metal dental restorations, all of which were added to the exclusion list in this latest update. Meanwhile, procedures like cosmetic surgeries (including rhinoplasty and liposuction) and platelet-rich plasma (PRP) treatments—which had already been restricted—remain off-limits unless deemed medically necessary. The resolution also removes a code related to neuropathic pain treatment, though the Ministry of Health has not yet clarified whether this affects specific medications or broader pain management protocols.

Who Is Affected—and How?

The changes impact four key groups:

1. Patients

Individuals relying on Colombia’s Entidades Promotoras de Salud (EPS)—the country’s health insurers—will now face out-of-pocket costs for the excluded treatments. For example:

• Patients with alopecia (hair loss) will no longer receive minoxidil at no cost, though some may qualify for partial subsidies under new “exceptional cases” protocols.
• Those with osteoarthritis losing coverage for diacerein may need to switch to alternative medications, potentially at higher personal expense.
• Cosmetic surgery patients (e.g., rhinoplasty or liposuction) will bear full costs unless their procedure is deemed medically necessary by an EPS-approved specialist.

2. Doctors and Clinics

Healthcare providers must now navigate stricter protocols for prescribing excluded treatments. The Ministry of Health has directed EPS to:

• Deny pre-authorization requests for the 117 excluded items unless they fall under rare “compassionate use” exceptions.
• Refer patients to alternative evidence-based treatments where available.
• Document all denials to justify funding decisions under new transparency rules.

Anesthesiologists, in particular, have publicly protested the exclusion of certain pain medications, arguing that the changes could compromise patient care for chronic conditions like neuropathic pain.

3. EPS Insurers

Colombia’s EPS—both public and private—must update their benefit packages by June 30, 2026, aligning with the new exclusion list. The Ministry of Health has warned that any insurer failing to comply risks losing accreditation. Financial analysts predict the changes could reduce EPS liabilities by up to 3% annually, though patient out-of-pocket spending may rise in certain therapeutic areas.

4. Pharmaceutical Companies

Drugmakers producing the excluded medications—such as minoxidil (commonly used for hair regrowth) and diacerein (an anti-inflammatory)—now face reduced market demand under the public system. Industry groups are lobbying for reconsideration of certain exclusions, arguing that patient access to these treatments remains critical in Colombia’s fragmented healthcare landscape.

Controversies and Criticisms

Not everyone supports the changes. Critics, including patient advocacy groups and medical associations, have raised several concerns:

“These exclusions disproportionately affect vulnerable populations who cannot afford alternative treatments. The government must ensure no one is left without access to essential medications.”

Anesthesiologists, represented by the Colegio Colombiano de Anestesiología, have urged the Ministry to reconsider the exclusion of certain pain medications, arguing that the changes could lead to under-treatment of chronic pain in Colombia’s public system.

Meanwhile, the Chamber of Commerce has warned that the exclusions could hurt pharmaceutical sales, particularly for companies specializing in dermatological and orthopedic treatments.

What’s Still Covered?

While the new resolution removes 117 items, the majority of Colombia’s Plan de Beneficios en Salud (PBS) remains intact. Key areas still fully covered include:

• Vaccinations and preventive care.
• Emergency room services and trauma care.
• Treatment for infectious diseases (e.g., tuberculosis, HIV).
• Maternity and pediatric services.
• Cancer therapies and chemotherapy.
• Essential medications for chronic conditions (e.g., insulin for diabetes, antihypertensives).

Patients unsure about their coverage should consult the official PBS list or contact their EPS directly.

Global Context: Colombia’s Healthcare Challenges

Colombia’s public health system faces long-standing structural challenges, including:

• High inequality: With a Gini coefficient of 53.9, Colombia ranks among the most unequal countries in Latin America, limiting access to care for low-income populations.
• Fragmented insurance: About 46% of Colombians rely on public health insurance (SISBÉN), while the remainder use private EPS or pay out-of-pocket.
• Resource constraints: The Ministry of Health’s budget represents just 5.5% of Colombia’s GDP, far below the 15% recommended by the WHO for universal healthcare.
• Corruption risks: Past scandals, such as Coosalud’s irregular debt transfers, have eroded public trust in health insurers.

The new exclusions are part of a broader effort to modernize Colombia’s healthcare financing, but analysts warn that deeper reforms—such as increasing public investment or expanding primary care—will be needed to ensure sustainable access for all.